Effect of sirolimus on renal ischaemia/reperfusion injury in normotensive and hypertensive rats

Transplant International

Volumn 17, Issue 8, 2004, Pages 432-441

  Viklický, Ondřej ^a   Bohmová, Radka ^a   Ouyang, Nengtai ^b   Honsová, Eva ^a   Lodererová, Alena ^a   Mandys, Václav ^c   Vítko, Štefan ^a   Lutz, Jens ^b   Heemann, Uwe W ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Hypertension; Ischaemia reperfusion injury; Kidney; Sirolimus; TGF ; Transgenic rat

Indexed keywords

ALLOANTIGEN; ANGIOTENSIN; AZAPERONE; CREATININE; IMMUNOSUPPRESSIVE AGENT; PLACEBO; RAPAMYCIN; RENIN; SUFENTANIL; SUFENTANIL CITRATE; TRANSFORMING GROWTH FACTOR BETA1; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLOMERULOSCLEROSIS; GLOMERULUS EPITHELIUM; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT NEPHROPATHY; KIDNEY DISEASE; KIDNEY HYPERTROPHY; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; REPERFUSION INJURY; TRANSGENIC ANIMAL; UNINEPHRECTOMY; VASCULAR DISEASE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD PRESSURE; CREATININE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; MALE; MICE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; RENIN; REPERFUSION INJURY; SIROLIMUS; UREA;

EID: 5444240696     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00147-004-0746-z     Document Type: Article

References (33)

1. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59:313.
2. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4:S30.
3. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339:1448.
4. Suematsu M, Suzuki H, Delano FA, Schmid-Schonbein GW. The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation 2002; 9:259.
5. Böhm M, Lee M, Kreutz R, et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995; 13:891.
6. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344:541.
7. Azuma H, Nadeau K, Takada M, Mackenzie HS, Tilney NL. Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/ reperfusion injury of a single kidney. Transplantation 1997; 64:190.
8. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59:3.
9. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action of immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31:335.
10. Fahrni JA, Berry GJ, Morris RE, Rosen GD. Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation 1997; 63:533.
11. Schtnid C, Heemann U, Azuma H, Tilney NL. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 1995; 60:729.
12. Viklicky O, Zou A, Muller V, Lácha J, Szabo A, Heemann U. SDZ RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000, 69:497.
13. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin and FK506. Transplantation 1995; 59:390.
14. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76:412.
15. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98:2277.
16. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59:655.
17. Morice MC, Serruys PW, Sousa JE, et al. RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773.
18. Rennke HG, Klein PS. Pathogenesis and significance of non-primary focal and segmental glomerulosclerosis. Am J Kidney Dis 1989; 13:443.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713.
20. Kurtz TW, Montano M, Chan L, Kabra P. Molecular evidence of genetic heterogeneity in Wistar-Kyoto rats: implications for research with the spontaneously hypertensive rat. Hypertension 1989; 13:188.
21. Witte K, Schnecke A, Schmidt T, Voll C, Kranzlin B, Lemmer B. Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR TGR(mREN2)27 rats. Gen Pharmacology 1999; 33:423.
22. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38:635.
23. Pagtalunan ME, Olson JL, Meyer TW. Contribution of angiotensin II to late renal injury after acute ischemia. J Am Soc Nephrol 2000; 11:1278.
24. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mREN-2)27 rat (TGR). Kidney Int 1998; 54:343.
25. Wolf G, Muller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92:1366.
26. Berg UB, Bohman SO, Widstam-Attorps U. Renal histological changes in relation to renal function and urinary protein excretion in IgA nephropathy. Arch Dis Child 1991; 66:593.
27. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 2001; 135:153.
28. Basile DP, Donohoe D, Roethe K, Oborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Renal Physiol 2001; 281:F887.
29. Böhmova R, Honsova E, Heemann U, Lodererova A, Matl I, Viklicky O. The effect of sirolimus on ischemia/reperfusion injury in transgenic hypertensive rat. Transplant Proc 2002; 34:3051.
30. Viklicky O, Muller V, Zou H, Szabo A, Vitko S, Heemann U. RAD reduces compensatory renal graft hypertrophy in a rat model of chronic rejection. Transplant Proc 2001; 33:2320.
31. Jain S, Bicknell GR, Whiting PH, Nicholson ML. Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. Transplant Proc 2001; 33:556.
32. Jain S, Bicknell GR, Nicholson ML. Molecular changes in extracellular matrix turnover after renal ischaemia-reperfusion injury. Br J Surg 2000; 87:1188.
33. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003; 5:73.